Argenx
ARGX
#503
Rank
NZ$80.70 B
Marketcap
NZ$1,300
Share price
1.76%
Change (1 day)
31.33%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): NZ$15.24

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$15.52. In 2024 the company made an earnings per share (EPS) of NZ$24.36 an increase over its 2023 EPS that were of NZ-$9.03.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$15.24-37.43%
2024NZ$24.36-369.77%
2023NZ-$9.03-60.46%
2022NZ-$22.8363.33%
2021NZ-$13.98-40.37%
2020NZ-$23.45183.47%
2019NZ-$8.27123.09%
2018NZ-$3.7154.93%
2017NZ-$2.3914.07%
2016NZ-$2.1013.05%
2015NZ-$1.86-36.34%
2014NZ-$2.92209.04%
2013NZ-$0.94-33.99%
2012NZ-$1.43185.59%
2011NZ-$0.50